Total Payments
$422,858
2024 Payments
$71,999
Companies
31
Transactions
289
Medicare Patients
9,379
Medicare Billing
$10.5M
Payment Breakdown by Category
Royalty/License$217,928 (51.5%)
Consulting$159,670 (37.8%)
Other$21,604 (5.1%)
Food & Beverage$15,894 (3.8%)
Travel$3,759 (0.9%)
Gifts$2,742 (0.6%)
Research$1,260 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $217,928 | 17 | 51.5% |
| Consulting Fee | $159,670 | 56 | 37.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,575 | 5 | 5.1% |
| Food and Beverage | $15,894 | 194 | 3.8% |
| Travel and Lodging | $3,759 | 13 | 0.9% |
| Gift | $2,742 | 2 | 0.6% |
| Unspecified | $1,260 | 1 | 0.3% |
| Entertainment | $28.78 | 1 | 0.0% |
Payments by Type
General
$421,598
288 transactions
Research
$1,260
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Oculus Surgical Inc. | $206,131 | 20 | $0 (2024) |
| Allergan, Inc. | $80,585 | 84 | $0 (2022) |
| Novartis Pharma AG | $43,538 | 8 | $0 (2021) |
| Alcon Laboratories Inc | $19,351 | 15 | $0 (2018) |
| Beaver-Visitec International, Inc. | $16,023 | 4 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $15,829 | 18 | $0 (2021) |
| Katalyst Surgical, LLC | $12,244 | 4 | $0 (2023) |
| Alimera Sciences, Inc. | $7,143 | 21 | $0 (2024) |
| Coherus Biosciences Inc. | $4,000 | 2 | $0 (2022) |
| Alcon Vision LLC | $3,234 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $71,999 | 28 | Oculus Surgical Inc. ($68,172) |
| 2023 | $68,491 | 36 | Oculus Surgical Inc. ($51,154) |
| 2022 | $64,658 | 40 | Oculus Surgical Inc. ($45,499) |
| 2021 | $72,334 | 32 | Oculus Surgical Inc. ($41,307) |
| 2020 | $55,051 | 26 | Novartis Pharma AG ($30,369) |
| 2019 | $32,945 | 46 | Allergan Inc. ($30,916) |
| 2018 | $21,556 | 42 | Allergan Inc. ($8,193) |
| 2017 | $35,825 | 39 | Allergan Inc. ($19,306) |
All Payment Transactions
289 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/05/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $47.83 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 11/18/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $28.32 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/13/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $30.44 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/04/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $30.53 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/19/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $188.67 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 10/14/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $26.35 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/11/2024 | Oculus Surgical Inc. | Hassan Tornambe Lens (Device) | Royalty or License | Cash or cash equivalent | $18,288.72 | General |
| 09/19/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $860.80 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 07/24/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $24.22 | General |
| Category: Immunology and Ophthalmology | ||||||
| 07/16/2024 | Oculus Surgical Inc. | — | Food and Beverage | Cash or cash equivalent | $75.30 | General |
| 07/05/2024 | Oculus Surgical Inc. | Hassan Tornambe Lens (Device) | Royalty or License | Cash or cash equivalent | $20,079.53 | General |
| 07/01/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $34.45 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/30/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $27.88 | General |
| Category: EYE CARE | ||||||
| 04/29/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $26.77 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/22/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $24.63 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/17/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $1,048.80 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 04/11/2024 | Oculus Surgical Inc. | Hassan Tornambe Lens (Device) | Royalty or License | Cash or cash equivalent | $16,228.84 | General |
| 04/04/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $129.26 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 03/27/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: EYE CARE | ||||||
| 03/25/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $23.38 | General |
| Category: OPHTHALMOLOGY | ||||||
| 03/20/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $1,057.20 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 03/07/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: Ophthalmology | ||||||
| 03/04/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $96.15 | General |
| Category: EYE CARE | ||||||
| 02/27/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $20.96 | General |
| Category: OPHTHALMOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| OUTCOMES RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $1,260 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 1,790 | 11,905 | $4.2M | $2.1M |
| 2022 | 10 | 2,270 | 10,611 | $4.8M | $2.6M |
| 2021 | 13 | 2,553 | 12,378 | $5.3M | $3.0M |
| 2020 | 12 | 2,766 | 11,497 | $4.8M | $2.8M |
Total Patients
9,379
Total Services
46,391
Medicare Billing
$10.5M
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 135 | 1,900 | $2.1M | $1.3M | 64.1% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 62 | 2,236 | $1.0M | $404,756 | 38.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 455 | 1,452 | $319,440 | $138,182 | 43.3% |
| 67028 | Injection of drug into eye | Office | 2023 | 199 | 1,074 | $377,750 | $117,634 | 31.1% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 12 | 3,120 | $140,400 | $90,721 | 64.6% |
| 92134 | Imaging of retina | Office | 2023 | 473 | 1,507 | $150,600 | $45,953 | 30.5% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 290 | 451 | $27,060 | $8,124 | 30.0% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 49 | 49 | $13,720 | $5,390 | 39.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 28 | 28 | $10,360 | $4,802 | 46.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 25 | 25 | $7,000 | $3,131 | 44.7% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 12 | 12 | $2,340 | $1,032 | 44.1% |
| 92250 | Photography of the retina | Office | 2023 | 37 | 37 | $4,625 | $1,025 | 22.2% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 13 | 14 | $1,610 | $540.92 | 33.6% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 153 | 2,082 | $2.2M | $1.5M | 66.6% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 89 | 3,158 | $1.5M | $704,301 | 47.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 585 | 1,722 | $378,840 | $158,848 | 41.9% |
| 67028 | Injection of drug into eye | Office | 2022 | 248 | 1,226 | $432,250 | $133,270 | 30.8% |
| 92134 | Imaging of retina | Office | 2022 | 567 | 1,236 | $123,550 | $36,660 | 29.7% |
| 92250 | Photography of the retina | Office | 2022 | 204 | 560 | $69,850 | $15,469 | 22.1% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2022 | 359 | 561 | $33,660 | $9,749 | 29.0% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 31 | 32 | $8,960 | $3,281 | 36.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 18 | 18 | $6,570 | $3,133 | 47.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 16 | 16 | $4,480 | $1,945 | 43.4% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 154 | 2,214 | $2.4M | $1.6M | 68.2% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2021 | 112 | 3,816 | $1.8M | $971,018 | 54.4% |
About Dr. Tarek Hassan, MD
Dr. Tarek Hassan, MD is a Ophthalmology healthcare provider based in Royal Oak, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1154367902.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tarek Hassan, MD has received a total of $422,858 in payments from pharmaceutical and medical device companies, with $71,999 received in 2024. These payments were reported across 289 transactions from 31 companies. The most common payment nature is "Royalty or License" ($217,928).
As a Medicare-enrolled provider, Hassan has provided services to 9,379 Medicare beneficiaries, totaling 46,391 services with total Medicare billing of $10.5M. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Royal Oak, MI
- Active Since 06/21/2006
- Last Updated 01/26/2022
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1154367902
Products in Payments
- Hassan Tornambe Lens (Device) $164,378
- OZURDEX (Drug) $44,927
- SUPER VIEW Lens, Disposable Contact, Hassan-Tornambe (Medical Supply) $41,307
- BLZ_BEOVU_OPHTHALMOLOGY (Drug) $30,369
- BEOVU (Drug) $20,154
- Constellation (Device) $16,433
- 25ga Stiff Slim DEX Hassan Forceps (Device) $12,244
- ILEVRO (Drug) $4,767
- ILUVIEN (Drug) $4,039
- Cimerli (Biological) $4,000
- YUTIQ (Drug) $3,033
- NGENUITY (Device) $2,742
- XIPERE (Drug) $1,559
- ACTHAR (Biological) $1,556
- EYP-1901 $1,525
- STELLARIS PC (Device) $752.98
- EYLEA (Biological) $445.49
- EYLEA AFLIBERCEPT INJECTION (Biological) $378.14
- Lucentis (Biological) $292.36
- SUSVIMO (Drug) $278.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Royal Oak
Dr. Jeremy Wolfe, Md, MD
Ophthalmology — Payments: $851,975
Ophthalmology $851,975
Dr. Kimberly Drenser, Md, MD
Ophthalmology — Payments: $70,185
Ophthalmology $70,185
Dr. Antonio Capone, Md, MD
Ophthalmology — Payments: $66,718
Ophthalmology $66,718
Dr. Alan Ruby, Md, MD
Ophthalmology — Payments: $64,841
Ophthalmology $64,841
Sandeep Randhawa, Md, MD
Ophthalmology — Payments: $58,625
Ophthalmology $58,625
Dr. George Williams, Md, MD
Ophthalmology — Payments: $46,707
Ophthalmology $46,707